Spravato (esketamine) — what it is, who qualifies, what it costs

FDA-approved nasal esketamine for treatment-resistant depression and MDD with acute suicidal ideation. Educational reference, eligibility checker, and cost calculator.

Check eligibility

About

Spravato is the brand name for esketamine, the S-enantiomer of ketamine, delivered as an intranasal spray. The FDA approved Spravato in March 2019 for treatment-resistant depression (TRD) in adults, and in August 2020 as adjunctive therapy for depressive symptoms in adults with MDD and acute suicidal ideation or behavior. Because of dissociation and sedation risks, Spravato is dispensed only under a Risk Evaluation and Mitigation Strategy (REMS) — patients receive each dose in a certified office and are monitored on-site for at least two hours afterward. This site is an independent educational reference; it is not a Janssen / Johnson & Johnson property.

What is Spravato?

Spravato (esketamine) is a nasal spray approved by the U.S. Food and Drug Administration in 2019 for adults with treatment-resistant depression (TRD), defined on the label as inadequate response to at least two antidepressants of adequate dose and duration in the current depressive episode. In 2020 the FDA expanded the label to include adults with major depressive disorder who have acute suicidal ideation or behavior, as an adjunct to a standard antidepressant.

Esketamine is the S-enantiomer of ketamine. It is a noncompetitive NMDA-receptor antagonist; its antidepressant mechanism is thought to involve rapid synaptic remodeling via downstream AMPA-receptor activity and BDNF signaling, distinct from monoaminergic antidepressants. Onset of antidepressant effect can be within hours to days, compared with the 4–8 week window typical for oral SSRIs/SNRIs.

Spravato is always given alongside an oral antidepressant — it is not a monotherapy on the label.

Who qualifies?

The two FDA-approved indications are:

  • TRD in adults: failure of at least two antidepressants of adequate dose/duration in the current episode.
  • MDD with acute SI in adults: as an adjunct to standard care for depressive symptoms in patients with MDD who have acute suicidal ideation or behavior.

Spravato is not approved for bipolar depression, anxiety disorders, OCD, PTSD, or pediatric use. Off-label use exists but falls outside the REMS framework.

Contraindications include aneurysmal vascular disease, arteriovenous malformation, and history of intracerebral hemorrhage. Hypersensitivity to esketamine, ketamine, or any excipient is also a contraindication. Pregnancy is a strong relative contraindication. Patients with cardiovascular instability require careful assessment because Spravato can transiently raise blood pressure.

Spravato eligibility checker

Quick screen against the FDA label criteria. Not a substitute for clinical assessment.

What to expect on visit day

  1. Pre-dose: baseline blood pressure and brief check-in. Patients are advised not to eat for two hours and not to drink fluids 30 minutes before dosing.
  2. Dose self-administration: the patient sprays the device into each nostril under direct staff supervision. Doses come in 28 mg devices; a typical session uses two or three devices (56 mg or 84 mg).
  3. Monitoring period: the patient stays on-site for at least two hours. Blood pressure is checked at 40 minutes and as needed. Dissociation typically peaks around 40 minutes and resolves within 90 minutes.
  4. Discharge: patients must not drive on the day of treatment and need a ride home. Most clinics require an arranged escort.

Typical visit length: 2 to 2.5 hours.

Insurance and coverage

Because Spravato is administered in-office, it is usually billed under the medical benefit (Medicare Part B / commercial medical), not the pharmacy benefit. Most commercial payers and Medicare cover Spravato when the FDA-label criteria are documented, but nearly all require prior authorization.

Janssen offers a copay support program (Spravato withMe) that may cap commercial out-of-pocket cost per dose; eligibility excludes government insurance. Uninsured patients with qualifying income may apply for the Johnson & Johnson Patient Assistance Foundation.

Coverage details and prior-auth requirements vary by plan and by state Medicaid program. Always verify with the patient's specific payer.

Spravato cost calculator

Estimate per-session and per-phase cost based on dose, insurance, and office fees.

Spravato FAQ

What is the REMS program and why does it exist?

REMS (Risk Evaluation and Mitigation Strategy) is an FDA-mandated safety program for drugs with significant risk. Spravato's REMS requires that the drug be dispensed and administered only at certified healthcare settings, that patients be monitored on-site for at least two hours post-dose, and that prescribers and patients enroll in the program. It exists primarily because of risks of sedation, dissociation, and abuse potential.

Why do I have to stay two hours after the dose?

The label requires at least two hours of post-dose monitoring because blood pressure can spike (typically peaking around 40 minutes), dissociation/sedation peak around the same time, and clinicians need to confirm safe recovery before discharge.

Can I drive after a session?

No. The label explicitly states patients should not drive or operate machinery until the next day after a restful sleep. Most clinics require a confirmed escort to arrange the ride home.

How is Spravato different from IV ketamine?

Ketamine is a 50/50 racemic mixture of R- and S-ketamine. Spravato is just the S-enantiomer (esketamine), delivered intranasally instead of intravenously. Spravato is FDA-approved for TRD and MDD with SI; IV ketamine for depression is used off-label. Bioavailability, pharmacokinetics, and reimbursement differ substantially.

How fast does Spravato work?

Some patients report improvement within hours to days of the first dose, but the label-defined response endpoint in pivotal trials was measured at week 4 of induction. Sustained benefit generally requires the full induction-and-maintenance schedule.

What is the induction schedule?

Induction is weeks 1 through 4: two sessions per week (8 sessions total). After that, the continuation phase shifts to once weekly for weeks 5–8, then maintenance is typically every one to two weeks based on clinical response.

Can I take my regular antidepressant alongside Spravato?

Yes — that's the design. Spravato is approved as adjunctive therapy. It is not a monotherapy on the label. Your prescriber continues an oral antidepressant alongside the Spravato schedule.

Is Spravato covered by Medicare?

Yes, Medicare Part B generally covers Spravato as a physician-administered drug. Beneficiaries pay the Part B deductible plus 20% coinsurance unless they have a Medigap or Medicare Advantage plan that further offsets cost.

Looking for a REMS-certified provider?

Janssen maintains the official treatment locator. We do not refer patients or operate clinics ourselves.

Open Spravato.com locator

Stay Updated

Get updates delivered to your inbox.

Recent Posts

View all posts